Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04413097

Delayed Cord Clamping With Oxygen In Extremely Low Gestation Infants

This study is being conducted to compare the incidence of preterm infants (up to 28+6 weeks GA) who achieve a peripheral oxygen saturation of 80 percent by 5 minutes of life (MOL) given mask CPAP/PPV with an FiO2 of 1.0 during DCC for 90 seconds (HI Group) to infants given mask CPAP/PPV with an FiO2 of .30 during DCC for 90 seconds (LO Group).

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

22 week–28 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of California Davis, Davis, California, United States

Loading trial locations.

About this study

Prenatal consent will be obtained on infant's with estimated gestational age up to 28+6 weeks. Shortly before delivery, infant's will be randomly assigned to receive either Low oxygen concentration (FiO2 .30) OR High oxygen concentration (FiO2 1.0) during 90 seconds of delayed cord clamping.

Randomization and intervention will remain blinded to the clinical care team during the entire study period. The research team member will open a randomization card when notified of a subject's impending birth, review the protocol with the obstetric provider performing the procedure, set-up the sterile stabilization bed, and note the time it takes from delivery until the clamping and cutting of the umbilical cord in both groups.

The research team member will set the oxygen blender as indicated by the randomization card and cover the blender to blind the FiO2 setting. The research team member will not be involved in the clinical care of the infant. The oxygen blender will be concealed from the clinical care team to ensure resuscitation maneuvers will not be biased.

Data will be submitted to the statistician, who will remain blinded to the intervention for the duration of the study.

At delivery, the infant will be placed on a platform that allows the infant to be close to the mother and the umbilical cord to remain intact for DCC. These beds are equipped with an oxygen blender, humidifier, t-piece resuscitator with mask, necessary to provide CPAP/PPV. At some centers the bed will be equipped with a radian warmer (Ceramotherm, Wyer GmbH, Germany) to maintain thermoregulation on the infant during delayed cord clamping.

If an infant is randomized to the DCC and Low Oxygen concentration (DCC LO group), the following procedure will ensue:

During delayed cord clamping, the infant will be gently stimulated by drying the infant with a sterile towel and provide CPAP by 30 seconds of life. During delayed cord clamping, breathing assistance with CPAP of 5 cm H20 and a FiO2 0.3 will be provided.

If an infant is randomized to the DCC and High Oxygen concentration (DCC HI group), the following procedure will ensue:

During delayed cord clamping, the infant will be gently stimulated by drying the infant with a sterile towel and provide CPAP by 30 seconds of life. During delayed cord clamping, breathing assistance with CPAP of 5 cm H20 and a FiO2 1.0 will be provided.

Patency of the airway in both groups will be assessed by a Colorimetric CO2 detector. Lack of color change will indicate that the airway is not patent (obstructed), the pressure is not sufficient to expand the lungs, there was excessive air leak, or there was no or inadequate pulmonary blood flow. If there is no color change, the neonatal provider will reposition and reattempt to open the airway, if no improvement they will initiate PPV (starting PIP of 20 cm H20) by 60 seconds of life. Cord clamping will occur at 90 seconds or greater and the infant will be transferred to a standard neonatal warmer and resuscitated per NRP guidelines.

Additionally, when available heart rate data will be collected using a non-invasive dry-electrode monitor, (NeoBeat, Laerdal Medical, Stavanger, Norway) and applied over the infant's chest or abdomen to provide continuous display of heart rate during 90 seconds of DCC.

Pulse oximetry, ECG sensors and Near-Infrared Spectroscopy (NIRS) sensors will be applied after cord clamping. The NIRS sensor will be placed on the infant's forehead. Cerebral StO2, SpO2, blood pressure (once in the NICU) and Heart rate will be recorded every two seconds and linked with other variables. These variables will continue to be recorded for the first 24 hours of life.

Blood sample will be collected at two different time points: Cord blood sample (T1: Cord blood collected after the cord is cut) and at 2 hours of life or NICU admission (T2). This is extra few drops of blood that is drawn from the baby for medical purposes (cord blood from cord gases and admission blood work up).

Samples will be tested for oxidized and reduced glutathione which are the most reliable and comprehensive biomarkers of oxidative stress.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • up to 28+6 weeks Gestational age
  • Single and Multiple pregnancy
  • All modes of delivery (vaginally or caesarean section)

Exclusion criteria

  • Parents decline consent
  • Congenital anomalies of the newborn
  • Bleeding Accreta
  • Monochorionic multiples with evidence of TTTS
  • Fetal or maternal risk (i.e. compromise)
  • Preterm Premature Rupture of Membranes prior to 20 weeks gestation
  • Parents request no resuscitation

Treatment and study plan

Delayed Cord Clamping with Low Oxygen concentration

Procedure

During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and low oxygen concentration (FiO2 0.30) will be provided.

Other names: DCC with Low Oxygen concentration, DCC LO group

Delayed Cord Clamping with High Oxygen concentration

Procedure

During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and high oxygen concentration (FiO2 1.0) will be provided.

Other names: DCC with High Oxygen concentration, DCC HI group

Primary outcomes

  1. Feasibility of administration of oxygen during delayed cord clamping and it's impact on the incidence of preterm infants (up to 28 +6 weeks) who achieve a peripheral oxygen saturation of 80 percent by 5 minutes of life

    Time frame: by 5 minutes of life

    To assess the feasibility and compare the incidence of preterm infants (up to 28+6 weeks GA) who achieve a peripheral oxygen saturation of 80 percent by 5 MOL given mask CPAP/PPV with an FiO2 of 1.0 during DCC for 90 seconds (HI Group) to infants given mask CPAP/PPV with an FiO2 of .30 during DCC for 90 seconds (LO Group).

Secondary outcomes

  1. All Grade IVH

    Time frame: Through study completion at hospital discharge, up to 6 months corrected gestational age (CGA)

    Any Intraventricular Hemorrhage (grades 1-4)

  2. Frequency of Grade III and IV intraventricular hemorrhage

    Time frame: Through study completion at hospital discharge, up to 6 months corrected gestational age (CGA)

    Intraventricular hemorrhages (grades 3-4) (bleeding in the brain parenchyma and/or ventricular dilation

  3. Resuscitation interventions

    Time frame: In the first 10 minutes of life

    Resuscitation interventions including intubation, chest compressions, medications

  4. Changes in heart rate (BPM) in the first 10 minutes of life

    Time frame: In the first 10 minutes of life

    Changes in heart rate (BPM) in the first 10 minutes of life

Other outcomes

  1. Changes in Inspired fractional oxygen (FiO2)

    Time frame: In the first 10 minutes of life

    Changes in Inspired fractional oxygen (FiO2)

  2. Duration of Hypoxia

    Time frame: The first 10 minutes of life in the delivery room

    Duration of Hypoxia (defined as oxygen saturation<25th percentile of target ranges defined by Dawson et al.) in the first 10 minutes after birth

  3. Duration of Hyperoxia

    Time frame: The first 10 minutes of life in the delivery room

    Duration of Hyperoxia (defined as oxygen saturation>95%) in the first 10 minutes after birth

  4. Changes in Mean airway pressure, MAP (cm H20)

    Time frame: In the first 10 minutes of life

    Changes in Mean airway pressure, MAP (cm H20)

  5. Duration of Positive Pressure Ventilation

    Time frame: The first 10 minutes of life in the delivery room

    Duration of positive pressure ventilation

  6. Blood pressures in the first 24 hours of life

    Time frame: In the first 24 hours of life

    Blood pressures every hour in the first 24 hours of life

  7. Cerebral tissue oxygenation in the first 24 hours of life

    Time frame: In the first 24 hours of life

    Cerebral tissue oxygenation in the first 24 hours of life

  8. Average oxygen saturation in the first 5 minutes after birth

    Time frame: by 5 minutes of life

    Oxygen saturation in the first 5 minutes after birth

  9. Average Heart rate in the first 5 minutes after birth

    Time frame: by 5 minutes of life

    Heart rate in the first 5 minutes after birth

  10. Intubation in the Delivery room or Neonatal Intensive Care Unit (NICU)

    Time frame: Birth through study completion at discharge, up to 6 months of corrected gestational age

    Intubation in the Delivery room or Neonatal Intensive Care Unit (NICU)

  11. Lowest and Highest Hemoglobin and/or Hematocrit

    Time frame: First 24 hours of life

    Hemoglobin and/or Hematocrit levels (before transfusion)

  12. Mean arterial blood pressure

    Time frame: First 24 hours of life

    Mean arterial blood pressure (collected hourly)

  13. Medication for Low Blood Pressure

    Time frame: First 24 hours of life

    Medication for Low Blood Pressure (e.g. hydrocortisone or pressors)

  14. CRIB-II (Clinical Risk Index for Babies)

    Time frame: First 12 hours of life

    CRIB-II (Clinical Risk Index for Babies)

  15. Duration of mechanical ventilation and/or CPAP

    Time frame: Birth through study completion at discharge, up to 6 months of corrected gestational age

    Number of days on mechanical ventilation and/or CPAP

  16. Surfactant administration

    Time frame: Immediately after intervention through study completion at hospital discharge, up to 6 months of corrected gestational age

    Surfactant administration

  17. Number of RBC Transfusions since birth

    Time frame: First 10 days after birth

    Number of RBC Transfusions since birth

  18. Patent Ductus Arteriosus requiring pharmacological or surgical treatment

    Time frame: Through study completion at discharge, up to 6 months of corrected gestational age

    Patent Ductus Arteriosus requiring pharmacological or surgical treatment

  19. Spontaneous Intestinal Perforation (SIP) requiring surgery or peritoneal drain

    Time frame: Through study completion at discharge, up to 6 months of corrected gestational age

    Spontaneous Intestinal Perforation (SIP) requiring surgery or peritoneal drain

  20. Necrotizing Enterocolitis (Modified Bell's stage 2-3)

    Time frame: Through study completion at discharge, up to 6 months of corrected gestational age

    Necrotizing Enterocolitis (Modified Bell's stage 2-3)

  21. Bronchopulmonary Dysplasia (mode of respiratory support administered at 36 weeks postmenstrual age; as defined and categorized in; Jensen, Dysart, Gantz, et al: Defining Bronchopulmonary Dysplasia) http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6775872/

    Time frame: Hospital course until 36 weeks PMA

    Bronchopulmonary Dysplasia (mode of respiratory support administered at 36 weeks postmenstrual age; as defined and categorized in; Jensen, Dysart, Gantz, et al: Defining Bronchopulmonary Dysplasia) http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6775872/

  22. Severe ROP (stage 3 or treated with laser or bevacizumab)

    Time frame: After the intervention through study completion at hospital discharge, up to 6 months of corrected gestational age

    Severe ROP (stage 3 or treated with laser or bevacizumab)

  23. Combined outcome of severe IVH and/or death

    Time frame: Through study completion at death or discharge, up to 6 months of corrected gestational age

    Combined outcome of severe IVH and/or death

  24. Death

    Time frame: Through study completion at death or discharge, up to 6 months of corrected gestational age

    Death

  25. SVC Flow

    Time frame: 6 hours of life

    Superior Vena Cava flow by echocardiography

  26. RVO

    Time frame: 6 hours of life

    Right Ventricular output by echocardiography

  27. Left Ventricular Output

    Time frame: 6 hours of life

    Left Ventricular output by echocardiography

  28. Cognitive Composite Score

    Time frame: 24 months corrected age

    Composite Score (cognitive 45-155; higher scores are better) as assessed by the Bayley Scales of Infant and Toddler Development Fourth Edition

  29. Language Composite Score

    Time frame: 24 months corrected age

    Composite Score (language 45-155; higher scores are better) as assessed by the Bayley Scales of Infant and Toddler Development Fourth Edition

  30. Motor Composite Score

    Time frame: 24 months corrected age

    Composite Score (motor 45-155; higher scores are better) as assessed by the Bayley Scales of Infant and Toddler Development Fourth Edition

  31. Cerebral Palsy

    Time frame: 24 months corrected age

    As assessed by Gross Motor Function Classification System (GMFCS) Levels 1-5

  32. Neurodevelopmental Outcome at 2 Years of Age

    Time frame: 22-26 months corrected age

    Overall and Domain Scores- Ages and Stages, 3rd ed. Questionnaire

  33. Pulsatility Index

    Time frame: 6 hours of life

    Pulsatility index calculated from Doppler of the Middle Cerebral Artery

  34. Resistive Index

    Time frame: 6 hours of life

    Resistive index calculated from Doppler of the Middle Cerebral Artery

  35. Changes in cerebral oxygenation saturation, StO2 (%)

    Time frame: In the first 10 minutes of life

    Changes in cerebral oxygenation saturation, StO2 (%)

  36. Changes in SpO2 (%) in the first 10 minutes of life

    Time frame: In the first 10 minutes of life

    Changes in SpO2 (%) in the first 10 minutes of life

  37. Inhaled Nitric Oxide

    Time frame: Immediately after intervention through study completion at hospital discharge, up to 6 months of corrected gestational age

    Use of Inhaled Nitric Oxide for Respiratory failure or Pulmonary Hypertension

  38. Glutathione (GSH/GSSG ratio)

    Time frame: from birth up to NICU admission or in the first 2 hours of life

    Assessment of oxidative biomarkers from birth up to 2 hours of life

  39. Thermoregulation

    Time frame: from 5 minutes of life up to NICU admission in the first 2 hours of life

    Assessment of thermoregulation (axillary temperatures measured in degrees Celsius) during delayed cord clamping on extremely low gestational infants

  40. Rate of Early Onset Sepsis

    Time frame: From birth up to 72 hours of life

    assessment of early onset sepsis with a positive blood or CSF culture at </= 72 HOL

  41. Rate of Late Onset Sepsis

    Time frame: From > 72 hours of life through study completion at death or discharge, up to 6 months of corrected gestational age

    assessment of late onset sepsis with a positive blood or CSF culture at > 72 HOL

Sponsors and collaborators

Lead sponsor

Sharp HealthCare

Other

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • Sharp Mary Birch Hospital for Women & Newborns

Registry information

Acronym: DOXIE

Important dates

Study start
2021
Primary completion
2025
Study completion
2026
First posted
Jun 2, 2020
Registry last updated
Jun 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.